A 55-year-old woman has been on propranolol hydrochloride sustained-release, flunarizine dihydrochloride, and topiramate 25 mg tablets for two years for migraine without resolution; what next steps should be taken to manage her refractory migraine?

Management of Refractory Migraine After Two Years of Failed Prophylaxis

This patient requires immediate referral to specialist care and consideration of CGRP monoclonal antibodies or onabotulinumtoxinA, as she has failed multiple first-line and second-line preventive medications. 1

Critical First Step: Rule Out Medication Overuse Headache (MOH)

Before advancing treatment, you must determine if this patient has developed MOH, which can mimic treatment-resistant migraine and cause preventive medications to fail:

• Assess acute medication use frequency: If she is using acute medications (triptans, NSAIDs, combination analgesics) ≥10-15 days per month, MOH is likely 1, 2
• If MOH is present: Withdraw the overused medication (abrupt withdrawal preferred except for opioids) and educate about the risk of medication overuse 1
• Critical caveat: Preventive medications will not work effectively during ongoing medication overuse 2

Determine Migraine Classification

Establish whether this is episodic migraine (EM) or chronic migraine (CM):

• Chronic migraine: ≥15 headache days per month for >3 months, with ≥8 days having migraine features
• Episodic migraine: <15 headache days per month

This distinction determines your next treatment options.

Treatment Algorithm for Refractory Migraine

Current Medication Assessment

The patient has already failed:

• Propranolol (first-line beta-blocker) 1
• Flunarizine (second-line calcium channel blocker) 1
• Topiramate 25 mg (first-line anticonvulsant) 1

Important consideration: Topiramate 25 mg is subtherapeutic. The effective dose range is 50-100 mg daily 3, 4, 5. However, after 2 years without dose escalation, this suggests either intolerance or inadequate trial.

Next-Line Treatment Options

For Chronic Migraine (if ≥15 headache days/month):

First-choice options 1:

1. CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab)

   • Reduce migraine days by 1.0-3.8 days per month 6
   • Well-tolerated with minimal adverse effects
   • Effective even after multiple preventive failures 3, 6
   • Administered monthly or quarterly by injection/infusion

2. OnabotulinumtoxinA (Botox)

   • 155-195 units to 31-39 sites every 12 weeks 1
   • Evidence-based for chronic migraine prevention 1
   • Not effective for episodic migraine 3

For Episodic Migraine (if <15 headache days/month):

Options include 3, 1:

1. CGRP monoclonal antibodies (third-line, but effective after multiple failures)
2. Atogepant (oral CGRP receptor antagonist) - reduces migraine days by 0.7-2.4 per month 6
3. Alternative second-line agents:
   • Amitriptyline 10-100 mg at night 1
   • Valproate 600-1,500 mg daily (contraindicated in women of childbearing potential) 1
   • Candesartan 16-32 mg daily 3, 1

Combination Therapy Consideration

If the patient has only partially responded to individual agents, combination therapy with beta-blocker plus topiramate at therapeutic doses has shown 75% response rate in refractory patients 7. However, this requires:

• Escalating topiramate to 50-100 mg daily (not the current 25 mg)
• Ensuring adequate propranolol dosing (80-160 mg daily for migraine) 4
• Close monitoring for adverse effects (17% discontinuation rate) 7

Specialist Referral is Mandatory

Refer to headache specialist or neurologist now 1. Rationale:

• Failed multiple first-line and second-line preventives
• Chronic migraine management is challenging and requires specialist expertise 1
• Access to CGRP antibodies and onabotulinumtoxinA typically requires specialist prescription
• Need for comprehensive evaluation of comorbidities (depression, anxiety, sleep disorders) that may be contributing to treatment resistance 1

Additional Management Considerations

Assess for Modifiable Risk Factors:

• Obesity: Consider topiramate dose escalation (associated with weight loss) 1
• Depression/anxiety: Consider amitriptyline if present 1
• Sleep disturbances: May require specific treatment 1

Non-Pharmacologic Interventions:

Add as adjuncts 3, 1:

• Physical therapy or aerobic exercise
• Biobehavioral therapy
• Neuromodulation devices

Optimize Acute Treatment:

Ensure she has effective acute medications:

• Triptans (if not overused)
• CGRP receptor antagonists (gepants) for acute treatment 3
• NSAIDs with antiemetics 1

Common Pitfalls to Avoid

1. Continuing ineffective preventives indefinitely: After 2 years without response, these medications should be discontinued
2. Missing MOH: This is the most common reason for apparent treatment resistance 2
3. Undertreating with subtherapeutic doses: The topiramate 25 mg dose is below the effective range
4. Delaying specialist referral: Guidelines explicitly recommend specialist care for chronic or refractory migraine 1
5. Ignoring comorbidities: Depression, anxiety, and obesity significantly impact treatment outcomes 1

The most recent and highest-quality evidence (2024 VA/DoD guidelines) supports CGRP monoclonal antibodies as the definitive next step for patients who have failed multiple oral preventives 3, with specialist referral being essential for optimal management 1.